Latest information on COVID-19
Support teaching, research, and patient care.
**DR MRUTHYUNJAYA IS AVAILABLE TO CARE FOR PATIENTS WITH EYE CANCERS AND RETINAL DISEASES**Prithvi Mruthyunjaya MD, MHS is Associate Professor of Ophthalmology at Stanford Univeristy, member of the Vitreoretinal Surgery Service and is the new Director of Ocular Oncology at the Byers Eye Institute. He is a board certified ophthalmologist who has completed two prestigious fellowships: the first in Vitreoretinal Surgery at Duke University and the second in Ocular Oncology at Moorfields Eye Hospital in London, England. He cares for patients with conditions related to cancer of the eye in both adults and children--either benign, pre-cancerous, or eye cancer. These conditions include ocular melanoma, hemangioma, cancers from other parts of the body which spread to the eye, Coats' disease, retinoblastoma, iris tumors (melanoma, cysts, metastatic lesions) and tumors of the conjunctiva including melanoma, and squamous cells carcinoma. He also manages the eye related side effects of chemotherapy treatments. He is an expert in using the most advanced diagnostic tests to make a personalized treatment plan for every patient. With his expertise in retinal surgery, he treats patients with a variety of advanced techniques including small instrument tumor biopsy, vitrectomy, and radiation therapy.As a retinal surgeon, he manages complicated retinal diseases including retinal detachment, macular holes, epiretinal membranes, and diabetic eye disease. His approach to any patient is to provide customized care for every patient and works closely with other experts at the Stanford Cancer Institute. Dr. Mruthyunjaya is actively involved in research in ocular cancer imaging, genetics, and new modalities of tumor biopsy. His passion lies in developing collaborative research networks and training the next generation of vitreoretinal surgeons. His academic contributions were recognized by the Heed, AOS-Knapp and Ronald G Michels foundations the American Society of Retina Specialists with a Senior Honor Award. He was recently listed as one of the worlds 150 most innovative retinal specialists.BIOGRAPHY:Dr. Mruthyunjaya was born in India and moved to Upstate New York at the age of 2. He was selected for the highly prestigious accelerated 6-year medical program completing his undergraduate studies at Rensselaer in 2 years then moving on to complete his medical studies at Albany Medical College where he was elected to the Alpha Omega Alpha honor society. At the Duke Eye Center in Durham, NC, he finished his Ophthalmology residency, Chief Residency, and clinical-research fellowships in Vitreoretinal surgery followed by an Ocular Oncology fellowship at the Moorfields Eye Hosptial in London, UK. As a fellow, he was recognized with the highest nationwide honors by the Heed, AOS-Knapp and Ronald G Michels foundations. He was on faculty at Duke from 2005-16 where developed an integrated Retina-Ocular Oncology program and was named a tenured Associate Professor of Ophthalmology and Radiation Oncology, Medical Director and Director of Ocular Oncology. He has enjoyed moving to the Bay area with his family.
Dr Mruthyunjaya has maintained a broad research interest with publications in both ocular oncology and retinal diseases. His focus is on multi-modal imaging of ocular tumors and understanding imaging clues that may predict vision loss after ocular radiation therapy. He coordinates multi-center research on the role of genetic testing and outcomes of treatments of ocular melanoma. In the field of retinal diseases, his interests are in intra-operative imaging to enhance surgical accuracy.
Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection
to treat primary indeterminate lesions and small choroidal melanoma.
View full details
Study in Subjects With Small Primary Choroidal Melanoma
The primary objective is to assess the safety, immunogenicity and efficacy of one of three
dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser
applications for the treatment of subjects with primary choroidal melanoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.